Companies › Thryv Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| THRV-1268 | – | Phase 2 | Long QT Syndrome (LQTS) 2 | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07277582 | THRV-1268 | Phase 2 | Long QT Syndrome (LQTS) 2 | Cardiovascular | Jun 2027 |
Cash of $9m on 2026-06-30; operating cash flow positive
Press releases filed as 8-K in the last year:
No annotated target.
–
Kiniksa Pharmaceuticals International Tectonic Therapeutic Nyrada AllRock Bio Zomagen Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.